276 related articles for article (PubMed ID: 33965249)
1. Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far.
Wong W; Alouani E; Wei A; Ryu YK; Chabot JA; Manji GA
Semin Oncol; 2021 Feb; 48(1):57-68. PubMed ID: 33965249
[TBL] [Abstract][Full Text] [Related]
2. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
3. Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.
Kumar S; Singh SK; Srivastava P; Suresh S; Rana B; Rana A
Adv Cancer Res; 2023; 159():113-143. PubMed ID: 37268394
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights.
Balsano R; Zanuso V; Pirozzi A; Rimassa L; Bozzarelli S
Curr Oncol; 2023 Mar; 30(4):3871-3885. PubMed ID: 37185406
[TBL] [Abstract][Full Text] [Related]
6. Precise Photodynamic Therapy by Midkine Nanobody-Engineered Nanoparticles Remodels the Microenvironment of Pancreatic Ductal Adenocarcinoma and Potentiates the Immunotherapy.
Qu C; Yuan H; Tian M; Zhang X; Xia P; Shi G; Hou R; Li J; Jiang H; Yang Z; Chen T; Li Z; Wang J; Yuan Y
ACS Nano; 2024 Feb; 18(5):4019-4037. PubMed ID: 38253029
[TBL] [Abstract][Full Text] [Related]
7. Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer.
Boelaars K; Goossens-Kruijssen L; Wang D; de Winde CM; Rodriguez E; Lindijer D; Springer B; van der Haar Àvila I; de Haas A; Wehry L; Boon L; Mebius RE; van Montfoort N; Wuhrer M; den Haan JMM; van Vliet SJ; van Kooyk Y
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37940346
[TBL] [Abstract][Full Text] [Related]
8. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
9. Immunologic Strategies in Pancreatic Cancer: Making
Ullman NA; Burchard PR; Dunne RF; Linehan DC
J Clin Oncol; 2022 Aug; 40(24):2789-2805. PubMed ID: 35839445
[TBL] [Abstract][Full Text] [Related]
10. The clinical terrain of immunotherapies in heterogeneous pancreatic cancer: unravelling challenges and opportunities.
Herpels M; Ishihara J; Sadanandam A
J Pathol; 2023 Aug; 260(5):533-550. PubMed ID: 37550956
[TBL] [Abstract][Full Text] [Related]
11. Activation of STING in the pancreatic tumor microenvironment: A novel therapeutic opportunity.
Chamma H; Vila IK; Taffoni C; Turtoi A; Laguette N
Cancer Lett; 2022 Jul; 538():215694. PubMed ID: 35489447
[TBL] [Abstract][Full Text] [Related]
12. Trials and tribulations of pancreatic cancer immunotherapy.
Principe DR; Korc M; Kamath SD; Munshi HG; Rana A
Cancer Lett; 2021 Apr; 504():1-14. PubMed ID: 33549709
[TBL] [Abstract][Full Text] [Related]
13. Advances in Pancreatic Ductal Adenocarcinoma Treatment.
Anderson EM; Thomassian S; Gong J; Hendifar A; Osipov A
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771675
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
15. Current Status of Immunotherapies for Treating Pancreatic Cancer.
Wu AA; Jaffee E; Lee V
Curr Oncol Rep; 2019 May; 21(7):60. PubMed ID: 31101991
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
Tarannum M; Vivero-Escoto JL
Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
[TBL] [Abstract][Full Text] [Related]
17. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
[TBL] [Abstract][Full Text] [Related]
18. Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer.
Sang W; Zhou Y; Chen H; Yu C; Dai L; Liu Z; Chen L; Fang Y; Ma P; Wu X; Kong H; Liao W; Jiang H; Qian J; Wang D; Liu YH
Cancer Discov; 2024 Feb; 14(2):326-347. PubMed ID: 37824278
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment.
Zhu YH; Zheng JH; Jia QY; Duan ZH; Yao HF; Yang J; Sun YW; Jiang SH; Liu DJ; Huo YM
Cell Oncol (Dordr); 2023 Feb; 46(1):17-48. PubMed ID: 36367669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]